

# A Study on the Development of USP1 inhibitor candidate as a New Synthetic Lethality Target for the Treatment of BRCA (-) and HRD (+) Cancer

AIGEN Sciences



ONCOLOGY	Candidate
Product Type	Small molecule
Indication	BRCA (-) cancers, HRD (+) cancers, CCNE-1 (+) cancers
Target	USP1
MoA(Mechanism of Action)	Synthetic lethality by the ubiquitination of PCNA
Competitiveness	KSQ4279: phase 1 ISM-3091: phase 1
Development Stage	candidate
Route of Administration	oral